Research-Based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2- Positive breast cancer in the NOAH Study

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 511-521

  Prat, Aleix ^a,b   Bianchini, Giampaolo ^d   Thomas, Marlene ^e   Belousov, Anton ^e   Cheang, Maggie C U ^g   Koehler, Astrid ^e   Gómez, Patricia ^a   Semiglazov, Vladimir ^h   Eiermann, Wolfgang ^f   Tjulandin, Sergei ⁱ   Byakhow, Mikhail ^j   Bermejo, Begoña ^c   Zambetti, Milvia ^d   Vazquez, Federico ^a   Gianni, Luca ^d   Baselga, José ^a,k  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Oncologia Medica   (Italy)

^e Roche   (Italy)

^f Frauenklinik vom Roten Kreuz   (Germany)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

ⁱ NN Blokhin Russian Cancer Centre   (Russian Federation)

^j N Semashko Hospital   (Russian Federation)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RNA ANALYSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84892776195     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0239     Document Type: Article

References (39)

1. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
2. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Prac Oncol 2008;5:531-42
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-72.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
5. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 2005;23:4265-74
6. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70
7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52
8. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
9. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16: 5222-32
10. Cheang MCU, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, et al. Responsiveness of intrinsic subtypes to adjuvant anthracyclinesubstitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res 2012;18:2402-12.
11. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012;18:4465-72.
12. Esserman L, Berry D, Cheang M, Yau C, Perou C, Carey L, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012;132:1049-62.
13. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype- ACOSOG Z1031. J Clin Oncol 2011;29:2342-9.
14. Parker J, Prat A, Cheang M, Lenburg M, Paik S, Perou C. Breast cancer molecular subtypes predict response to anthracycline/taxane-based chemotherapy [abstract]. In: Proceedings of the 32nd CTRC-AACR San Antonio Breast Cancer Symposium; 2009 Dec 10-13; San Antonio, TX. Philadelphia, PA: AACR; 2009. Abstract nr 2019.
15. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
16. Perou C, Parker J, Prat A, Ellis M, Philip S. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 2010;11:718-19
17. Prat A, Parker J, Fan C, Perou C. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012;135:301-6.
18. Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, et al. Seventeen-gene signature from enriched Her2/Neu mammary tumorinitiating cells predicts clinical outcome for human HER2+:ERA* breast cancer. Proc Natl Acad Sci U S A 2012;109:5832-37.
19. Gluck S, Ross J, Royce M, McKenna E, Perou C, Avisar E, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 2011:1-11.
20. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expressionbased assays for breast oncologists. Nat Rev Clin Oncol 2011;9: 48-57
21. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38.
22. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117.
23. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2- positive breast cancer in The North Central Cancer Treatment Group N9831 trial. J Clin Oncol 2013;31:2115-22.
24. Scaltriti M, Eichhorn PJ, Cort-es J, Prudkin L, Aura C, Jiménez J, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Nat Acad Sci U S A 2011;108:3761-6
25. Eichhorn PJA, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. Cancer Res 2008;68: 9221-30
26. Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu- Lehtinen P-L, et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 2013;105:960-7
27. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011;29:651-9
28. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor- I receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst 2001;93:1852-7
29. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379: 633-40
30. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxanebased chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 2012;13:135-44
31. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2011;13:25-32.
32. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Annal Oncol 2008;19:1090-6
33. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23
34. Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 2012;31:203-9
35. Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25: 118-45
36. Paik S, Tang G, Shak S, Kim C, Baker J, KimW, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast Cancer. J Clin Oncol 2006;24:3726-34.
37. Knauer M, Mook S, Rutgers E, Bender R, Hauptmann M, van de Vijver M, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010; 120:655-61.
38. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
39. Fan C, Prat A, Parker J, Liu Y, Carey L, Troester M, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 2011;4:3